Compare Cassava Sciences Inc (FLNA) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Sony Group Corp — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Sony Group Corp trades at $21.23 (market cap $123.02B). The key difference: Sony Group Corp is far larger — about 2315× Cassava Sciences Inc's market cap, and Sony Group Corp pays a 0.76% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SONY | |
|---|---|---|
Market Cap | $53.14M | $123.02B |
Sector | Health | Technology |
52-Week High | $4.64 | $30.26 |
52-Week Low | $1.09 | $19.32 |
Enterprise Value | -$33.43M | $119.51B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Sony trades at $20.80, up 0.58% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong operating cash flow of $2.32 trillion in 2025, but faces a projected net loss in 2026. Analyst consensus is bullish with 68.75% buy ratings, while recent news highlights Sony's strategic shift to digital-only PlayStation games by 2028.
The outlook is mixed: strong cash flow and analyst support provide upside potential, but 2026's projected loss and bearish technicals pose near-term risks. Investors should weigh the digital transition's long-term benefits against execution challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
